DNA vaccines: Progress and challenges

Journal of Immunology

Volumn 175, Issue 2, 2005, Pages 633-639

  Donnelly, John J ^a   Wahren, Britta ^b   Liu, Margaret A ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; GLYCOPROTEIN GP 160; PLASMID DNA;

ALLERGY; ANIMAL CELL; ANTIGEN PRESENTATION; CLINICAL RESEARCH; CROSS PRESENTATION; HUMAN; IMMUNE RESPONSE; IMMUNOPHARMACOLOGY; IN VIVO STUDY; INFECTION; LABORATORY DIAGNOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; SHORT SURVEY; VACCINATION;

EID: 23244456102     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.2.633     Document Type: Short Survey

References (77)

1. Wolff, J. A., R. W. Malone, P. Williams, W. Chong, G. Acsadi, A. Jani, and P. L. Felgner. 1990. Direct gene transfer into mouse muscle in vivo. Science 247: 1465-1468.
2. Ulmer, J. B., J. J. Donnelly, S. E. Parker, G. H. Rhodes, P. L. Felgner, V. J. Dwarki, S. H. Gromkowski, R. R. Deck, C. M. DeWitt, A. Friedman, et al. 1993. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259: 1745-1749.
3. Donnelly, J. J., J. B. Ulmer, J. W. Shiver, and M. A. Liu. 1997. DNA vaccines. Annu. Rev. Immunol. 15: 617-648.
4. + T cells after gene gun immunization. J. Exp. Med. 188: 1075-1082.
5. Barry, M. A., and S. A. Johnston. 1997. Biological features of genetic immunization. Vaccine 15: 788-791.
6. Manam, S., B. J. Ledwith, A. B. Barnum, P. J. Troilo, C. J. Pauley, L. B. Harper, T. G. Griffiths II, Z. Niu, L. Denisova, T. T. Follmer, et al. 2000. Plasmid DNA vaccines: tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA. Intervirology 43: 273-281.
7. Fu, T. M., J. B. Ulmer, M. J. Caulfield, R. R. Deck, A. Friedman, S. Wang, X. Liu, J. J. Donnelly, and M. A. Liu. 1997. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol. Med. 3: 362-371.
8. Iwasaki, A., C. A. Torres, P. S. Ohashi, H. L. Robinson, and B. H. Barber, 1997. The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites. J. Immunol. 159: 11-14.
9. Corr, M., D. J. Lee, D. A. Carson, and H. Tighe. 1996. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J. Exp. Med. 184: 1555-1560.
10. Spetz, A. L., A. S. Sorensen, L. Walther-Jallow, B. Wahren, J. Andersson, L. Holmgren, and J. Hinkula. 2002. Induction of HIV-1-specific immunity after vaccination with apoptotic HIV-1/murine leukemia virus-infected cells. J. Immunol. 169: 5771-5779.
11. Srivastava, P. 2002. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu. Rev. Immunol. 20: 395-425.
12. Leifert, J. A., M. P. Rodriguez-Carreno, F. Rodriguez, and J. L. Whitton. 2004. Targeting plasmid-encoded proteins to the antigen presentation pathways. Immunol. Rev. 199:40-53.
13. Kovacsovics-Bankowski, M., K. Clark, B. Benacerraf, and K. L. Rock. 1993. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc. Natl. Acad. Sci. USA 90: 4942-4946.
14. Sigal, L. J., S. Crotty, R. Andino, and K. L. Rock. 1999. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 398: 77-80.
15. + cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res. Hum. Retroviruses 16: 273-282.
16. Krieg, A. M. 2002. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20: 709-760.
17. Spies, B., H. Hochrein, M. Vabulas, K. Huster, D. H. Busch, F. Schmitz, A. Heit, and H. Wagner. 2003. Vaccination with plasmid DNA activates dendritic cells via Toll-like recepror 9 (TLR9) but functions in TLR9-deficient mice. J. Immunol. 171: 5908-5912.
18. Calarota, S. A., and D. B. Weiner. 2004. Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants. Immunol. Rev. 199: 84-99.
19. Lee, A. H., Y. S. Suh, and Y. C. Sung. 1999. DNA inoculations with HIV-1 recombinant genomes that express cytokine genes enhance HIV-1 specific immune responses. Vaccine 17: 473-479.
20. Rollman, E., J. Hinkula, J. Arteaga, B. Zuber, A. Kjerrstrom, M. Liu, B. Wahren, and K. Ljungberg. 2004, Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies. Gene Ther. 11: 1146-1154.
21. Barouch, D. H., S. Santra, J. E. Schmitz, M. J. Kuroda, T. M. Fu, W. Wagner, M. Bilska, A. Craiu, X. X. Zheng, G. R. Krivulka, et al. 2000. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290: 486-492.
22. Barouch, D. H., A. Craiu, M. J. Kutoda, J. E. Schmitz, X. X. Zheng, S. Santra, J. D. Frost, G. R. Krivulka, M. A. Lifton, C. L. Crabbs, et al. 2000. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc. Natl. Acad. Sci. USA 97: 4192-4197.
23. Moore, A. C., W. P. Kong, B. K. Chakrabarti, and G. J. Nabel. 2002. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice. J. Virol. 76: 243-250.
24. Montgomery, D. L., J. J. Donnelly, J. W. Shiver, M. A. Liu, and J. B. Ulmer. 1994. Protein expression in vivo by injection of polynucleotides. Curr Opin Biotechnol. 5: 505-510.
25. Chen, M. C., B. Doe, M. Schaefer, C. E. Greer, M. Selby, G. R. Otten, and S. W. Barnett. 2000. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene. J. Virol. 74: 2628-2635.
26. Wang, R., D. L. Doolan, T. P. Le, R. C. Hedstrom, K. M. Coonan, Y. Charoenvit, T. R. Jones, P. Hobart, M. Margalith, J. Ng, et al. 1998. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282: 476-480.
27. Shiver, J. W., M. E. Davies, Y. Yasutomi, H. C. Perry, D. C. Freed, N. L. Letvin, and M. A. Liu. 1997. Anti-HIV env immunities elicited by nucleic acid vaccines. Vaccine 15: 884-887.
28. + T-cell-depleted rhesus macaques. J. Virol. 75: 1547-1550.
29. Nakano, I., G. Maertens, M. E. Major, L. Virvitski, J. Dubuisson, A. Fournillier, G. De Marrynoff, C. Trepo, and G. Inchauspe. 1997. Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode. J. Virol. 71: 7101-7109.
30. Zur Megede, J., G. R. Otten, B. Doe, H. Liu, L. Leung, J. B. Ulmer, J. J. Donnelly, and S. W. Barnett. 2003. Expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA vaccines. J. Virol. 77: 6197-6207.
31. Otten, G. R., B. Doe, M. Schaefer, M. Chen, M. J. Selby, C. Goldbeck, M. Hong, F. Xu, and J. B. Ulmer. 2000. Relative potency of cellular and humoral immune responses induced by DNA vaccination. Intervirology 43: 227-232.
32. Ji, H., T. L. Wang, C. H. Chen, S. I. Pai, C. F. Hung, K. Y. Lin, R. J. Kurman, D. M. Pardoll, and T. C. Wu. 1999. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the anthumor immunity of DNA vaccines against murine human papillomavitus type 16 E7-expressing tumors. Hum. Gene Ther. 10: 2727-2740.
33. Rodriguez, F., J. Zhang, and J. L. Whitton. 1997. DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J. Virol. 71: 8497-8503.
34. Fu, T. M., L. Guan, A. Friedman, J. B. Ulmer, M. A. Liu, and J. J. Donnelly. 1998. Induction of MHC class I-restricted CTL response by DNA immunization with ubiquitin-influenza virus nucleoprotein fusion antigens. Vacant 16: 1711-1717.
35. Mwau, M., I. Cebere, J. Sutton, P. Chikoti, N. Winstone, E. G. Wee, T. Beattie, Y. H. Chen, L. Dorrell, H. McShane, et al. 2004. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J. Gen. Virol. 85:911-919.
36. Nkolola, J. P., E. G. Wee, E. J. Im, C. P. Jewell, N. Chen, X N. Xu, A. J. McMichael, and T. Hanke. 2004. Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa. Gene Ther. 11: 1063-1080.
37. Ljungberg, K., E. Rollman, L. Eriksson, J. Hinkula, and B. Wahren. 2002. Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. Virology 302: 44-57.
38. Sedegah, M., Y. Charoenvit, J. Aguiar, J. Sacci, R. Hedstrom, S. Kumar, A. Belmonte, D. E. Lanar, T. R. Jones, E. Abot, et al. 2004. Effect on antibody and T-cell responses of mixing five GMP-produced DNA plasmids and administration with plasmid expressing GM-CSF. Genes Immun. 5: 553-561.
39. O'Hagan, D. T., M. Singh, and J, B. Ulmer. 2004. Microparticles for the delivery of DNA vaccines. Immunol. Rev. 199: 191-200.
40. D'Souza, S., V. Rosseels, O. Denis, A. Tanghe, N. De Smet, F. Jurion, K. Palflier, N. Castiglioni, A. Vanonckelen, C. Wheeler, and K. Huyger. 2002. Improved tuberculosis DNA vaccines by formulation in canonic lipids. Infect. Immun. 70: 3681-3688.
41. Evans, R. K., D. M. Zhu, D. R. Casimiro, D. K. Nawrocki, H. Mach, R. D. Troutman, A. Tang, S. Wu, S. Chin, C. Ahn, et al. 2004. Characterization and biological evaluation of a microparticle adjuvant formulation for plasmid DNA vaccines. J. Pharm. Sci. 93: 1924-1939.
42. Luby, T. M., G. Cole, L. Baker, J. S. Kornher, U. Ramstedt, and M. L. Hedley. 2004. Repeated immunization with plasmid DNA formulated in plasmid (lactide-co-glycolide) micro particles is well tolerated and stimulates durable T cell responses to the tumor-associated antigen cytochrome P450 1B1. Clin. Immunol. 112:45-53.
43. Ulmer, J. B., C. M. DeWitt, M. Chastain, A. Friedman, J. J. Donnelly, W. L. McClements, M. J. Caulfield, K. E. Bohannon, D. B. Volkin, and R. K. Evans. 1999. Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vaccine 18: 18-28.
44. Denis-Mize, K. S., M. Dupuis, M. L. MacKichan, M. Singh, B. Doe, D. O'Hagan, J. B. Ulmer, J. J. Donnelly, D. M. McDonald, and G. Orr. 2000. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther. 7: 2105-2112.
45. Dupuis, M., K. Denis-Mize, C. Woo, C. Goldbeck, M. J. Selby, M. Chen, G. R. Otten, J. B. Ulmer, J. J. Donnelly, G. Ott, and D. M. McDonald. 2000. Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J. Immunol. 165: 2850-2858.
46. Denis-Mize, K., M. Dupuis, M. Singh, C. Woo, M. Ugozzoli, D. O'Hagan, J, Donnelly, G. Ott, and D. M. McDonald. 2003. Mechanisms of increased immunogenicity for DNA-based vaccines absorbed onto cationic microparticles. Cell. Immunol. 225:12-20.
47. Moreno, S., L. Lopez-Fuertes, A. J. Vila-Coro, F. Sack, C. A. Smith, S. A. Konig, B. Wittig, M. Schroff, C. Juhis, C. Junghans, and M. Timon. 2004, DNA immunisation with minimalistic expression constructs. Vaccine 22: 1709-1716.
48. Davis, H. L., M. L. Michel, and R. G. Whalen. 1993. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum. Mol. Genet. 2: 1847-1851.
49. Coney, L., B. Wang, K. E. Ugen, J. Boyer, D. McCallus, V. Srikantan, M. Agadjanyan, C. J. Pachuk, K. Herold, M. Merva, et al. 1994. Facilitated DNA inoculation induces anti-HIV-1 immunity in-vivo. Vaccine 12: 1545-1550.
50. Widera, G., M. Austin, D. Rabussay, C. Goldbeck, S. W. Barnett, M. Chen, L. Leung, G. R. Otten, K. Thudium, M. J. Selby, and J. B. Ulmer. 2000. Increased DNA vaccine delivery and immunogenicity by electroporauon in vivo. J. Immunol. 164: 4635-4640
51. Wang, Z., P. J. Troilo, X. Wang, T. G. Griffiths, S. J. Pacchione, A. B. Barnum, L. B. Harper, C. J. Pauley, Z. Niu, L. Denisova, et al. 2004. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther. 11: 711-721.
52. Zanetti, M., P. Castiglioni, M. Rizzi, M. Wheeler, and M. Gerloni. 2004. B lymphocytes as antigen-presenting cell-based genetic vaccines. Immunol. Rev. 199: 264-278.
53. Tang, D. C., M. De Vit, and S. A. Johnston. 1992. Genetic immunization is a simple method for eliciting an immune response. Nature 356: 152-154.
54. Lundholm, P., A. C. Leandersson, B. Christensson, G. Bratt, E. Sandstrom, and B. Wahren. 2002. DNA mucosal HIV vaccine in humans. Virus Res. 82: 141-145.
55. Kim, T. W., J. H. Lee, L. He, D. A. Boyd, J. M. Hardwick, C. F. Hung, and T. C. Wu. 2005. Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res. 65: 309-316.
56. Bower, J. F., T. D. Green, and T. M. Ross. 2004. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1. Virology 328: 292-300.
57. Drew, D. R., J. S. Boyle, A. M. Lew, M. W. Lightowlers, P. J. Chaplin, and R. A. Strugnell. 2001. The comparative efficacy of CTLA-4 and L-selectin targeted DNA vaccines in mice and sheep. Vaccine 19: 4417-4428.
58. Barnett, S., G. Otten, I. Srivastava, J. zur Megede, Y. Lian, M. Schaefer, H. Liu, R. R. Deck, J. Donnelly, J. Polo, et al. 2003. Enhanced DNA prime-protein boost vaccines induce potent immune responses against HIV-1. In Retroviruses of Human AIDS and Related Animal Diseases, XIII Cent Gardes Symposium. Elsevier, New York, p. 145-153
59. + T-cell-depleted rhesus macaques. J. Virol. 75: 1547-1550.
60. Ferrari, M. E., G. Hermanson, and A. Rolland. 2004. Development of anthrax DNA vaccines. Curr. Opin. Mol. Ther. 6: 506-512.
61. Tanghe, A., S. D'Souza, V. Rosseels, O. Denis, T. H. Ottenhoff, W. Dalemans, C. Wheeler, and K. Huygen. 2001. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect. Immun. 69: 3041-3047.
62. Kongkasuriyachai, D., L. Bartels-Andrews, A. Stowers, W. E. Collins, J. Sullivan, J. Sattabongkot, M. Torii, T. Tsuboi, and N. Kumar. 2004. Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28-evaluation of homologous and heterologous antigen-delivery prime-boost strategy. Vaccine 22: 3205-3213.
63. Sedegah, M., M. Belmonte, J. E. Epstein, C. A. Siegrist, W. R. Weiss, T. R. Jones, M. Lu, D. J. Carucci, and S. L. Hoffman. 2003. Successful induction of CD8 T cell-dependent protection against malaria by sequential immunization with DNA and recombinant poxvirus of neonatal mice born to immune mothers. J. Immunol. 171: 3148-3153.
64. McConkey, S. J., W. H. Reece, V. S. Moorthy, D. Webster, S. Dunachie, G. Butcher, J. M. Vuola, T. J. Blanchard, P. Gothard, K. Watkins, et al. 2003. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9: 729-735.
65. Moorthy, V. S., E. B. Imoukhuede, S. Keating, M. Finder, D. Webster, M. A. Skinner, S. C. Gilbert, G. Walraven, and A. V. Hill. 2004. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J. Infect. Dis. 189: 2213-2219.
66. Letvin, N. L., Y. Huang, B. K. Chakrabarti, L. Xu, M. S. Seaman, K. Beaudry, B. Korioth-Schmitz, F. Yu, D. Rohne, K. L. Martin, et al. 2004. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J. Virol. 78: 7490-7497.
67. Moore, A. C., and A. V. Hill. 2004. Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunol. Rev. 199: 126-143.
68. + lymphocytes. Science 283: 857-860.
69. Tryniszewska, E., J. Nacsa, M. G. Lewis, P. Silvera, D. Montefiori, D. Venzon, Z. Hel, R. W. Parks, M. Moniuszko, J. Tartaglia, et al. 2002. Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy. J. Immunol. 169: 5347-5357.
70. Lisziewicz, J., J. Trocio, L. Whitman, G. Varga, J. Xu, N. Bakare, P. Erbacher, C. Fox, R. Woodward, P. Markham, et al. 2005. Derma Vir: a novel topical vaccine for HIV/ AIDS. J. Invest. Dermatol. 124: 160-169.
71. MacGregor, R. R., R. Ginsberg, K. E. Ugen, Y. Baine, C. U. Kang, X. M. Tu, T. Higgins, D. B. Weiner, and J. D. Boyer. 2002. T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev. AIDS 16: 2137-2143.
72. Hejdeman, B., A. C. Bostrom, R. Matsuda, S. Calarota, R. Lenkei, E. L. Fredriksson, E. Sandstrom, G. Bratt, and B. Wahren. 2004. DNA immunization with HIV early genes in HIV type 1-infected patients on highly active antiretroviral therapy. AIDS Res. Hum. Retroviruses 20: 860-870.
73. MacGregor, R. R., J. D. Boyer, K. E. Ugen, P. Tebas, T. J. Higgins, Y. Baine, R. B. Ciccarelli, R. S. Ginsberg, and D. B. Werner. 2005. Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral "blips". Vaccine 23: 2066-2073.
74. Calarota, S., G. Bratt, S. Nordlund, J. Hinkula, A. C. Leandersson, E. Sandstrom, and B. Wahren. 1998. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 351: 1320-1325.
75. Lu, W., L. C. Arraes, W. T. Ferreira, and J. M. Andrieu. 2004. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat. Med. 10: 1359-1365.
76. Stevenson, F. K., C. H. Ottensmeier, P. Johnson, D. Zhu, S. L. Buchan, K. J. McCann, J. S. Roddick, A. T. King, F. McNicholl, N. Savelyeva, and J. Rice. 2004. DNA vaccines to attack cancer. Proc. Natl. Acad. Sci. USA 101: 14646-14652.
77. Gilboa, E., and J. Vieweg. 2004. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol. Rev. 199: 251-263.